PTPN11 and colorectal carcinoma: However, current studies do not provide insights into the biological mechanisms underlying the clinical behavior of SHP2, and exploratory studies combined with SHP2 correlated regulators or downstream targets should be performed to further discriminate CRC patients with favorable or unfavorable outcomes.